--- title: "Target Validation and Lead Discovery: From a Biological Claim to a Molecule" description: "A target is worth pursuing only if changing it changes disease and if a molecule can reach it. This stop covers genetic and chemical validation, screening for hits, and the properties a hit has to gai" canonical: https://lightmysky.com/learn/science/target-validation-and-lead-discovery-from-a-biological-claim-to-a-molecule-mt_xHWq5Rg85r source: https://lightmysky.com/learn/science/target-validation-and-lead-discovery-from-a-biological-claim-to-a-molecule-mt_xHWq5Rg85r.md retrieved: 2026-09-12 --- > **Agent view.** This is the Markdown twin of the page, for tools and assistants. > When to use this site, and the call that answers each job: https://lightmysky.com/agent-instructions.md > API description (OpenAPI 3.1): https://lightmysky.com/openapi.json · Authentication: https://lightmysky.com/auth.md > Pricing: https://lightmysky.com/pricing.md · Catalog: https://lightmysky.com/llms.txt · Full catalog: https://lightmysky.com/llms-full.txt > Every machine-readable file on this domain: https://lightmysky.com/.well-known/ai-catalog.json > Ask for Markdown with `Accept: text/markdown`, a `.md` address, or `?mode=agent`. # Target Validation and Lead Discovery: From a Biological Claim to a Molecule A target is worth pursuing only if changing it changes disease and if a molecule can reach it. This stop covers genetic and chemical validation, screening for hits, and the properties a hit has to gain before it counts as a lead. Subject: Science · Area: Biochemistry & Molecular Biology · Ages 23 to 24 Page: https://lightmysky.com/learn/science/target-validation-and-lead-discovery-from-a-biological-claim-to-a-molecule-mt_xHWq5Rg85r ## Ready when they can - Distinguish genetic validation of a target from chemical validation, and say what each leaves open - Explain what a screening hit has to survive before anyone calls it a lead - Relate potency, selectivity and exposure to whether a molecule can work in a body ## Lesson: From disease gene to a molecule that works Target validation asks whether changing a target changes disease, and whether a molecule can reach it. Genetic evidence shows the target matters in disease but leaves open whether a drug can reach and modulate it safely. Chemical evidence shows modulation is possible but leaves open whether patients benefit. A serious program wants both legs before spending at scale. Drugs act by binding receptors, blocking transporters, or altering enzymes, and the dose response curve reveals much. Agonists push while antagonists block, and affinity decides who wins the seat at low doses. This binding logic is what chemical validation must demonstrate in cells, not just in a well. **Example.** A screening hit sits at the very start of a long road. Before anyone says lead, the hit must confirm in fresh assays, show dose response, survive counterscreens against related targets, dissolve well enough to test, and act in cells. Each gate removes artifacts that looked promising in one well. **Tip.** Judge every candidate on three numbers together. Potency sets the concentration needed at the target. Selectivity sets how much hits elsewhere. Exposure sets whether free drug reaches that level in tissue and stays there. A brilliant binder with no exposure is a reagent, not a medicine. **Recap.** Prove the target both ways, gate every hit hard, and demand potency with selectivity and exposure. ## Practice 8 questions on this page, each with its working shown. ## Needs first - [Double-Reciprocal Plots and Telling Inhibitor Types Apart](https://lightmysky.com/learn/science/double-reciprocal-plots-and-telling-inhibitor-types-apart-mt_9y397ROu9X) - [Allosteric Enzymes, Cooperativity and the Sigmoid Curve](https://lightmysky.com/learn/science/allosteric-enzymes-cooperativity-and-the-sigmoid-curve-mt_u8f5QLHq-g) ## Opens up - [Clinical Trials: Phases, Endpoints and Why Most Candidates Fail](https://lightmysky.com/learn/science/clinical-trials-phases-endpoints-and-why-most-candidates-fail-mt_xKBKzSYxLh)